Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Asset Writedowns and Impairment (2020 - 2024)

Arcadia Biosciences (RKDA) has disclosed Asset Writedowns and Impairment for 6 consecutive years, with -$4.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Asset Writedowns and Impairment fell 3014.94% year-over-year to -$4.5 million, compared with a TTM value of -$4.3 million through Sep 2025, down 2914.94%, and an annual FY2024 reading of $154000.0, down 65.32% over the prior year.
  • Asset Writedowns and Impairment was -$4.5 million for Q3 2025 at Arcadia Biosciences, down from $154000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $2.0 million in Q4 2021 and bottomed at -$4.5 million in Q3 2025.
  • Average Asset Writedowns and Impairment over 5 years is $56615.4, with a median of $169000.0 recorded in 2023.
  • The sharpest move saw Asset Writedowns and Impairment soared 1580.0% in 2023, then tumbled 3014.94% in 2025.
  • Year by year, Asset Writedowns and Impairment stood at $2.0 million in 2021, then plummeted by 98.59% to $28000.0 in 2022, then skyrocketed by 800.0% to $252000.0 in 2023, then tumbled by 38.89% to $154000.0 in 2024, then plummeted by 3014.94% to -$4.5 million in 2025.
  • Business Quant data shows Asset Writedowns and Impairment for RKDA at -$4.5 million in Q3 2025, $154000.0 in Q3 2024, and $252000.0 in Q3 2023.